A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

Table 1 Efficacy data of rituximab monotherapy depending on MZL subtypes

MZL subtype		Number of patients	OR (%)	CR (%)
EMZL	[11]	112	73	45
EMZL	[12]	138	78	56
SMZL [11]		122	92	58
NMZL [11]		3	33	0

MZL marginal zone lymphoma, EMZL extranodal marginal zone lymphoma, SMZL splenic marginal zone lymphoma, NMZL nodal marginal zone lymphoma, OR overall response, CR complete response

ISSN: 1471-2407